Donna Cryer has channeled her personal experience as an IBD and liver transplant patient into a distinguished career in professional advocacy spanning two decades. She was the first patient to lead the American Liver Foundation in its thirty-six year history, serving as Chair of the Board before stepping in as interim CEO.

For almost a decade previously, Ms. Cryer, founded and led CryerHealth, LLC, providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations, and emerging technology firms on patient engagement in health information technology, drug discovery, and clinical decision-making.

Her e-health experience includes participating in the launch of the Office of National Coordinator for HIT (ONC) consumer engagement campaign and serving on the ONC technical expert panel on patient-generated health data. She has participated as a member of the White House e-health equity taskforce and the judging panel on the White House design challenge on innovating the electronic patient medical record. Her blog, DCpatient – An Impatient Patient’s Perspective from Washington, DC, and twitter feed @DCpatient are listed as top resources for insights into emerging e-patients and patient advocates.

Ms. Cryer is a patient representative to the U.S. Food and Drug Administration, a merit reviewer for the Patient Centered Outcomes Research Institute (PCORI), and a member of Stakeholder Advisory Group to the NIH Learning Health System Research Collaboratory. Additionally, she is on the Board of the Personalized Medicine Coalition, a member of the Patient and Consumer Advisory Council for the Center for Medical Technology Policy, and Treasurer of HarborPath, a patient assistance program for those living with HIV/AIDS and HCV.

Ms. Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and received a Juris Doctorate from the Georgetown University Law Center.

Health, Healthcare, Healthcare Policy, Women's Health, Pharmaceutical, Liver Disease, Patient safety, Healthcare Quality & Safety,